Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation,

• Autor(a) principal: Komnitski,Melpone
• Data de Publicação: 2020
• Outros Autores: Komnitski,Angelo, Komnitski Junior,Amilton, Castro,Caio César Silva de
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Anais brasileiros de dermatologia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000400009
• topic: Janus kinases; Phototherapy; Vitiligo

Abstract Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inhibitors associated with phototherapy. This report details the case of a patient with rheumatoid arthritis associated with vitiligo in treatment for two years, whose condition partially improved initially after eight months of oral tofacitinib at a dose of 5 mg twice a day, without exposure to ultraviolet radiation and with continuous improvement during these two years of treatment.